Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 6, 2003, Pages 841-849

  Gibson, Ronald L ^a   Emerson, Julia ^b   McNamara, Sharon ^b   Burns, Jane L ^b   Rosenfeld, Margaret ^b   Yunker, Ann ^b   Hamblett, Nicole ^b   Accurso, Frank ^b   Dovey, Mark ^b   Hiatt, Peter ^b   Konstan, Michael W ^b   Moss, Richard ^b   Retsch Bogart, George ^b   Wagener, Jeffrey ^b   Waltz, David ^b   Wilmott, Robert ^b   Zeitlin, Pamela L ^b   Ramsey, Bonnie ^b   Cohen, Morty ^b   Foster, Jessica ^b   Hallmark, Charlene ^b   Hasbrouck, Trish ^b   Hilliard, Jay ^b   Hilliard, Kate ^b   Ingham, Lori ^b   Johnson, Craig ^b   Kociela, Vikki ^b   Kronmal, Richard ^b   Locke, Sally ^b   Mundahl, Jean ^b   Osberg, Iris ^b   Penvari, Churee ^b   Stapp, Jenny ^b   Watts, Sharon ^b   Wertz, Marcia ^b   Williams, Judy ^b   more..

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Bronchoalveolar lavage; Lung; Pseudomonas

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT; CREATININE;

ARTICLE; AUDIOMETRY; BRONCHOSPASM; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEARING DISORDER; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY DYSFUNCTION; LOWER RESPIRATORY TRACT; LUNG LAVAGE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SIDE EFFECT; TREATMENT OUTCOME; AGE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG MONITORING; GENETICS; GENOTYPE; GRAM NEGATIVE INFECTION; HETEROZYGOTE; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; KIDNEY DISEASE; MICROBIOLOGY; OROPHARYNX; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; SAFETY; SPUTUM;

ADMINISTRATION, INHALATION; AGE FACTORS; ANTI-BACTERIAL AGENTS; AUDIOMETRY; BRONCHOALVEOLAR LAVAGE FLUID; CARRIER STATE; CHILD, PRESCHOOL; CREATININE; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GENOTYPE; HEARING DISORDERS; HUMANS; KIDNEY DISEASES; MALE; OROPHARYNX; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SAFETY; SEVERITY OF ILLNESS INDEX; SPUTUM; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 0037445216     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200208-855OC     Document Type: Article

References (54)

1. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease, 8th ed. New York: McGraw-Hill; 2001. p. 521-588.
2. Kosorok MR, Zeng L, West SHE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrell PM. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-287.
3. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
4. Cystic Fibrosis Foundation. Patient Registry 2000 [annual report]. Bethesda, MD: Cystic Fibrosis Foundation; 2001.
5. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-1322.
6. Singh PK, Shaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-764.
7. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416:695-696.
8. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:547-554.
9. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921.
10. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
11. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, et al. Longitudinal assessment of Pseudomonas aeruginosa in infants with cystic fibrosis. J Infect Dis 2001;183:444-452.
12. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001;32:356-366.
13. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutièrrez JP, Hull J, Olinsky A, Phelan EM. Robertson CF, Phelan PD. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-1204.
14. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B. Döoring G, von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
15. Frederickson B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.
16. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-984.
17. Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois M, Gérardin M, Brahimi N, Navarro J, Bingen E. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001;32:288-292.
18. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A. Robertson CF. Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
19. Ramsey BW, Wentz KR, Smith AL, Richardson M, Williams-Warren J, Hedges DL, Gibson R, Redding G, Lent K, Harris K. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144:331-337.
20. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267-275.
21. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-328.
22. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746.
23. Rosenfeld M, Cohen M, Ramsey B. Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy and pitfalls. Clin Pulm Med 1997;4:101-112.
24. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoy K, Schell R, Borowitz D, Konstan M, Retsch-Bogart G, Wilmott RW, et al. Serum and lower respiratory tract drug concentrations produced by tobramycin for inhalation in young children with cystic fibrosis. J Pediatr 2001;139:572-577.
25. Gibson RL, Emerson J, Mcnamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Moss R, Konstan M, Retsch-Bogart G, Waltz D, Wilmott R, Wagener J, Zeitlin P, Ramsey B. A randomized controlled trial of inhaled tobramycin in young children with cystic fibrosis: eradication of Pseudomonas from the lower airway [abstract 356]. Pediatr Pulmonol 2002(Suppl 24).
26. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BR, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163.
27. Barends DM, Zwaan CL, Hulshoff A. Micro-determination of tobramycin in serum by high-performance liquid chromatograph with ultraviolet detection. J Chromatogr 1981;225:417-426.
28. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34:1129-1135.
29. Krzewinski J, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol 2001;39:3597-3602.
30. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-538.
31. Jolley ME, Stroupe SD, Wang CJ. Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem 1981;27:1190-1197.
32. Thompson G, Wilson WR. Clinical application of visual reinforcement audiometry. Semin Hearing 1984;5:85-99.
33. Gravel JS. Behavioral assessment of auditory function. Semin Hearing 1989;10:216-228.
34. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
35. Emerson SS. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Biometrics 1995;51:1152-1162.
36. Emerson SS, Fleming TR. Parameter estimation following group sequential hypothesis testing. Biometrika 1990;77:875-892.
37. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111:955-962.
38. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994;88:203-211.
39. Geller DE, Rosenfeld M, Waltz D, Wilmott R. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003;123:28-36.
40. Bryan LE. Aminoglycoside resistance. In: Bryan LE, editor. Antimicrobial drug resistance. Orlando, FL: Academic Press: 1984. p. 241-251.
41. Evans DJ, Brown MR, Allison DG, Gilbert P. Susceptibility of bacterial biofilms to tobramycin: role of specific growth rate and phase in the division cycle. J Antimicrob Chemother 1990;25:585-591.
42. Ring E, Eber E, Erwa W, Zach MS. Urinary N-acetyl-β-D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation. Arch Dis Child 1998;78:540-543.
43. Noah TL, Black HR, Cheng P-W, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997;175:638-647.
44. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-191.
45. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
46. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164:1425-1431.
47. Meyer KC, Sharma A. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 1997;156:1536-1540.
48. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
49. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1995;132:761-765.
50. Ramphal R, Lhermitte M, Filliat M, Roussel P. The binding of antipseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 1988;22:483-490.
51. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19:10-15.
52. Long FF, Castile RG, Brody AS, Hogan MJ, Flucke RL, Filbrun DA, McCoy KS. Lungs in infants and young children: improved thin section CT with noninvasive controlled-ventilation technique - initial experience. Radiology 1999;212:588-593.
53. Castile RG, Filbrun D, Flucke R, Frankline W, McCoy K. Adult type pulmonary function tests in infants without respiratory diseases. Pediatr Pulmonol 2000;30:215-227.
54. Turner DJ, Lanteri CJ, LeSouef PN, Sly PD. Improved detection of abnormal respiratory function using forced expiration from raised lung volume in infants with cystic fibrosis. Eur Respir J 1994;7:1995-1999.